We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Point-of-Care D-Dimer Tests Exclude Deep Vein Thrombosis

By LabMedica International staff writers
Posted on 10 Nov 2010
Five point-of-care (POC) blood tests for fibrin degradation product D-dimer have been evaluated for their accuracy in diagnosing deep vein thrombosis (DVT). More...


D-dimer is a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. POC D-dimer tests enable rapid exclusion of DVT without the need to refer a patient for conventional laboratory-based D-dimer testing.

Five D-dimer tests were evaluated at the University Medical Center Utrecht, (Utrecht, the Netherlands). The scientists analyzed data of 577 prospectively identified consecutive primary care patients suspected to have DVT. The patients underwent four quantitative D-dimer tests (Vidas, Pathfast, Cardiac, and Triage) and one qualitative test (Clearview Simplify). Ultrasonography was performed as the reference method. They evaluated the tests for the accuracy of their measurements and submitted a questionnaire to 20 users to assess the user-friendliness of each test.

The Vidas D-dimer test (bioMerieux; Marcy-l'Etoile, France), combines a two-step enzyme immunoassay sandwich method with fluorescent detection. The Pathfast D-dimer test (Mitsubishi Kagaku Iatron, Inc.; Tokyo, Japan), is a chemiluminescent enzyme immunoassay, which contains two D-dimer monoclonal antibodies, one labeled with alkaline phosphatase and the other coated with magnetic particles. The Cardiac D-dimer test (Roche Diagnostics, F. Hoffmann-La Roche Ltd., Basel, Switzerland), is based on a dual monoclonal antibody sandwich comprising a poly-streptadivin-biotin capture system with a gold particle label. The Triage D-dimer test (Biosite; San Diego CA, USA), uses single-marker fluorescence sandwich immunoassay uses the 3B6 D-Dimer antibody. The Clearview Simplify D-dimer test (Inverness Medical; Princeton, NJ, USA), is based on immunochromatography, and the test uses two D-dimer specific murine monoclonal antibodies, one of which is conjugated to colloidal gold particles.

All D-dimer tests showed negative predictive values higher than 98%. Sensitivity was high for all POC tests, with a range of 0.91 for Clearview Simplify to 0.99 for Vidas. Specificity varied between 0.39 for Pathfast and 0.64 for Clearview Simplify. The quantitative POC tests showed similar and high discriminative power for DVT. The quantitative Vidas and Pathfast devices showed limited user-friendliness for primary care, owing to a laborious calibration process and long analyzer warm-up time compared to the Cardiac and Triage. For the qualitative Clearview Simplify assay, no analyzer or calibration was needed, but interpretation of a test result was sometimes difficult because of poor color contrast. The study was published on September 15, 2010 in Clinical Chemistry.

Related Links:

University Medical Center Utrecht
bioMerieux
Mitsubishi Kagaku Iatron, Inc.
Roche Diagnostics
Biosite
Inverness Medical




New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.